Adial Pharmaceuticals 주식 (NASDAQ: ADIL)

에 대한 최신 뉴스 Adial Pharmaceuticals (NASDAQ:ADIL) 주식

Adial Pharmaceuticals

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals Inc

RBC Capital analyst Drew McReynolds reiterates Corus Entertainment (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CJR#TSX">CJR</a>) with a Sector Perform and maintains C$0.2 price target.

News

Price Target

Reiteration

Analyst Ratings

TSX:CJR

TSX:CJR/B

RBC Capital Reiterates Sector Perform on Corus Entertainment, Maintains C$0.2 Price Target

Select Medical Corporation today announced it signed a membership interest purchase agreement with Ballad Health to jointly operate Select Specialty Hospital – Tri-Cities, a critical illness recovery hospital in Kingsport, Tenn. The facility, licensed as long-term acute care, will be a hospital-in-hospital located in Ballad Health's Indian Path Community Hospital.&nbsp;
Select Medical will serve as the majority owner and managing partner of the 46-bed joint venture hospital with Ballad Health. The hospital, which is currently owned and operated by Select Medical, will relocate from Ballad Health's Bristol Regional Medical Center to Indian Path Community Hospital following regulatory approval.

Select Medical Signs Membership Interest Purchase Agreement With Ballad Health To Jointly Operate Select Specialty Hospital – Tri-Cities

RSLS

ReShape Lifesciences Regains Nasdaq Compliance Under Minimum Stockholders Equity Requirement

On June 25, 2025, Ralliant Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RALW#NYSE">RALW</a>), a spin-off of Fortive Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTVW#NYSE">FTVW</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) <a href="https://gsbresearch.com/product/spinoff-analysis-fortive-and-ralliant-begin-when-issued-trading/">commenced when-issued trading</a> on the NYSE. 
Earlier on September 4, 2024, FTV announced plans to separate its Precision Technologies business into a separate publicly listed company, Ralliant Corp, via a tax-free spin-off transaction. The parent will retain the Intelligent Operating Solutions (IOS) and Advanced Healthcare Solutions (AHS) business segments, boasting a portfolio with 50% recurring revenue. We see the spin-off as a move to streamline operations and accelerate business growth, thereby unlocking value for shareholders. The spin-off will allow Fortive to focus on high-growth, high-margin businesses in software and connected devices. The Precision Technologies business is more capital-intensive and has stable but slower growth than the parent. The separation will allow Ralliant to allocate capital and resources more efficiently towards its needs, such as R&amp;D for advanced instrumentation or acquisitions within its niche.
The record date for the distribution of Ralliant shares was June 16, 2025. Each FTV shareholder will receive 1 share of Ralliant for every 3 shares of FTV held as of the record date. The regular-way trading will begin on June 30, 2025. Ralliant will trade under the ticker ‘RAL' and Fortive (ex Ralliant) will continue to trade under the ticker ‘FTV'. The spin-off of Ralliant will be effective on June 28. The transaction is intended to qualify as tax-free to Fortive shareholders.
Following the completion, Olumide Soroye, the current leader of Fortive's intelligent operations division, will assume the position of CEO. Meanwhile, Tami Newcombe, the current overseer of the Precision Technologies and Advanced Health-Care units, will take charge of Ralliant Corp.
As part of the transaction, FTV (ex RAL) will receive $1.15 billion in dividend from Ralliant Corp. RAL will assume debt to pay the cash dividend to FTV and commence its journey as a standalone company with a leverage of 1.9x.
INVESTMENT HIGHLIGHTS
Fortive (ex Ralliant)
Post the separation, Fortive will comprise the portfolio brands such as Accruent, Fluke, Gordian, Censis, Provation, currently operating under Fortive's two business segments – Intelligent Operating Solutions (iOS) and Advanced Healthcare Solutions (AHS). The two business segments generate nearly 50% recurring revenue and have demonstrated lower volatility across cycles.
FTV (ex Ralliant) will be $4 billion in revenues, with 65% adjusted gross margins and 29% adjusted EBITDA margins. The business generated about $1 billion in free cash flow over the last twelve months with an adjusted net income to FCF conversion of more than 100%. Over the last five years, it has delivered 4% core revenue CAGR.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="906" height="117" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27103225/image-8.png" alt="" class="wp-image-14985" style="width:850px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27103225/image-8.png 906w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27103225/image-8-300x39.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27103225/image-8-768x99.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></figure>
Intelligent Operating Solutions (IOS). IOS is Fortive's largest segment, accounting for nearly 70% of the revenue post spin-off. It houses flagship brands such as Fluke (electrical and industrial test tools), Industrial Scientific (gas detection and worker safety), Accruent and Gordian (enterprise asset management), and ServiceChannel (facility maintenance SaaS platform). The segment serves diverse end markets predominantly industrial, government, retail &amp; consumer. Geographically, U.S. accounts for the largest revenue contribution at 56% of total, followed by Europe at 17% and China at 8%.
Advanced Healthcare Solutions (AHS). The AHS segment supplies critical workflow solutions critical for patient care. This includes instrument sterilization solutions, instrument tracking, biomedical test tools, radiation detection and safety monitoring, and end-to-end clinical productivity software and solutions. The AHS segment has a recurring revenue base at nearly 80% with adjusted EBITDA margins in high 20s. The addressable market across AHS verticals exceeds $10 billion, with low single-digit to mid-single digit growth potential.
Capital Structure. As part of the transaction, FTV (ex RAL) will receive $1.15 billion in dividend from Ralliant Corp. Of which, $700 million will be used to repay debt. The remaining will be used for share buyback under its $550 million share repurchase authorization program. Pro forma debt post spin-off is expected to be $3.2 billion, with cash &amp; cash equivalents at $1.2 billion. Based on TTM Q1 2025 adjusted EBITDA, leverage is 2.7x, with the target to bring it down to 2.5x in the next 12-18 months.
Ralliant Corp
Ralliant Corp will include the Precision Technologies business comprising a portfolio of brands such as Gems, Tektronix, Setra, Qualitrol, among others. It offers advanced instrumentation and precision measurement solutions to aerospace, defense, electronics, automotive, and industrial manufacturing.
The Company will operate via two segments &#8211; Test and Measurement (~56% of total sales) and Sensors and Safety Systems (44% of total sales).
Capital Structure
As part of the transaction, Ralliant will issue new debt of $1.15 billion via a term loan. The proceeds will be used to fund the cash distribution to Fortive. Pro forma cash post the transaction will be $150 million, implying a net debt of $1.0 billion. Additionally, RAL will have access to a total liquidity of $900 million comprising an undrawn revolving credit facility of $750 million and $150 million in undrawn term loans. Based on TTM Q1 2025 adjusted EBITDA, leverage is 1.9x, which is within the Company's target range of 1.5x-2.0x.
Financial Outlook
FTV (ex RAL)
We expect FTV (ex RAL) to deliver revenue growth of 3.6% in FY25. We expect margins to expand, supported by higher mix of recurring revenue and operating leverage. As such, we model EBITDA margins of 29% in FY25, up 50 bps YOY. The combination of solid revenue growth and margin expansion should drive EPS higher. We model adjusted EPS of $2.56 in FY25, up 6% YOY.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="710" height="148" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27104037/image-9.png" alt="" class="wp-image-14987" style="width:506px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27104037/image-9.png 710w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27104037/image-9-300x63.png 300w" sizes="(max-width: 710px) 100vw, 710px" /><figcaption class="wp-element-caption">Source: GSBR Research Estimates, Company filings</figcaption></figure>
Ralliant Corp (RAL)
We expect RAL to deliver revenue growth of 3.5% in FY25 and 4.0% in FY:26. We expect adjusted EBITDA to grow faster than revenue, implying margin expansion. As such, we model EBITDA margins of 23.7% in FY25 and 23.9% in FY:26. We forecast adjusted EPS of $3.40 in FY25 and $3.60 in FY26.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="704" height="170" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27104157/image-10.png" alt="" class="wp-image-14988" style="width:501px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27104157/image-10.png 704w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27104157/image-10-300x72.png 300w" sizes="(max-width: 704px) 100vw, 704px" /><figcaption class="wp-element-caption">Source: GSBR Research Estimates, Company filings</figcaption></figure>
Valuation
FTV (ex RAL) 
We value FTV (ex RAL) using the EV/EBITDA multiple. We value IOS segment at 19x 2026E adjusted EBITDA of $1,049 million, and ASH segment at 12.6x 2026E adj. EBITDA of $395 million, in line with the peer group average. Corporate expense is valued at 12x. We use debt of ~$3.2 billion and cash of $1.2 billion (factoring in ~$1.15 billion of proceeds from RAL which will be used to pare debt). We assume ~339 million shares outstanding. Our 12-month price target is $62.70.
Ralliant Corp (RAL) 
We value RAL using the EV/EBITDA multiple. We apply a multiple of 12.4x 2026E adjusted EBITDA of $557 million, at a discount to the peer group average given RAL's lower growth and margin profile and higher debt. We assume ~113 million shares outstanding. Our 12-month price target is $52.40.

Conclusion: Of the two, Fortive (ex RAL) seems a better investment opportunity and could attract higher investor interest given its higher margin profile, reducing debt and share buyback program.

Equities

Long Ideas

Opinion

Tech

Trading Ideas

Fortive Corporation Common Stock When-Issued

FTVW

RALW

Fortive Or Its Spin-Off Ralliant: Which Stock Is A Better Buy?

WETH

WeTouch Secures Nasdaq Extension To File Delinquent 10-K And 10-Q Reports

RBC Capital analyst Irene Nattel reiterates Alimentation Couche-Tard (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ATD#TSX">ATD</a>) with a Outperform and maintains C$94 price target.

TSX:ATD

RBC Capital Reiterates Outperform on Alimentation Couche-Tard, Maintains C$94 Price Target

Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) today announced that it has entered into definitive agreements in a registered direct offering with a single institutional investor for the purchase and sale of approximately $17.2 million of shares of Common Stock and pre-funded warrants at a price of $7.50 per share of Common Stock. Upon closing of the offering, the Company will have fully utilized its shelf registration statement.

Offerings

Cyngn Announces $17.2M Registered Direct Offering At $7.50/Shr

WIIM

Alpha Pro Tech shares are trading higher after the company's board authorized a $2 million expansion of its share repurchase program.

Buybacks

Alpha Pro Tech Board Authorizes $2M Expansion Of Share Repurchase Program

In a potential game-changer for the cryptocurrency mining sector, Morgan Stanley has forecasted that CoreWeave Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) proposed acquisition of Core Scientific Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) could boost the Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) miner&#8217;s market capitalization by an impressive $2.8 billion.
What Happened: This Morgan Stanley analysis was shared by Eric Jackson from EMJ Capital amid renewed takeover discussions between the two companies, as reported by the Wall Street Journal, with a deal possibly finalizing within weeks if negotiations proceed smoothly.
&#8220;While the potential terms of a deal were not released, the estimated profits from the current contracts exceed Core Scientific's market cap by ~$2.8B,&#8221; said Jackson in his X post, quoting Morgan Stanley.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Morgan Stanley on the potential <a href="https://twitter.com/search?q=%24CRWV&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$CRWV</a> &#8211; <a href="https://twitter.com/search?q=%24CORZ&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$CORZ</a> deal: While the potential terms of a deal were not released, the estimated profits from the current contracts exceed Core Scientific's market cap by ~$2.8B (with CORZ market cap at ~$4.95B today).
&mdash; Eric Jackson (@ericjackson) <a href="https://twitter.com/ericjackson/status/1938421603253235836?ref_src=twsrc%5Etfw">June 27, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Core Scientific, currently valued at approximately $4.87 billion, rejected $5.75 per share offer from CoreWeave a year ago. The company operates one of North America's largest digital infrastructure platforms focused on bitcoin mining and hosting.
The company's strategic 12-year hosting partnership with CoreWeave, which provides 590 MW of capacity across 12 contracts valued at $10 billion, underpins this growth.
&#8220;Core Scientific receives a 75%-80% profit margin on the CoreWeave contract, which implies that Core Scientific receives a profit of ~$7.75bn at the midpoint,&#8221; Jackson highlighted in another post.
See Also: <a href="https://www.benzinga.com/markets/equities/25/06/46108861/microsoft-is-playing-chess-and-others-are-playing-checkers-dan-ives-says-msft-could-be-a-5-trillion-company-in-18-months">Microsoft Is &#8216;Playing Chess, And Others Are Playing Checkers:&#8217; Dan Ives Says MSFT Could Be A $5 Trillion Company In 18 Months</a>
Why It Matters: CoreWeave, a $75.87 billion cloud infrastructure giant serving AI workloads for clients like Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), is funding up to $750 million in data center build-outs, with Core Scientific contributing just $104 million.
&#8220;Core Scientific receives a 75%-80% profit margin on the CoreWeave contract, which implies that Core Scientific receives a profit of ~$7.75bn at the midpoint,&#8221; explained Jackson.
Price Action: CRWV shares were up 1.97% in premarket on Friday and ended 0.89% lower on Thursday. It has risen by 295.20% since its listing in March.
Benzinga Edge Stock Rankings shows that CRWV had a stronger price trend over the short, medium, and long term. Its value ranking was poor at the 9.72nd percentile. The details are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="156" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27083111/CRWV-EDGE-new-1024x156.png" alt="" class="wp-image-964838" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27083111/CRWV-EDGE-new-1024x156.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27083111/CRWV-EDGE-new-300x46.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27083111/CRWV-EDGE-new-768x117.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27083111/CRWV-EDGE-new.png 1110w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
CORZ shares were up 7.89% in premarket on Friday and ended 33.01% higher on Thursday. It has risen by 12.98% on a year-to-date.
Benzinga Edge Stock Rankings shows that CORZ had a stronger price trend over the short, medium, and long term. Its momentum ranking was solid; however, its value ranking was poor at the 16.3rd percentile. The details of other metrics are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="162" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27082907/CORZ-EDGE-1024x162.png" alt="" class="wp-image-964835" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27082907/CORZ-EDGE-1024x162.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27082907/CORZ-EDGE-300x47.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27082907/CORZ-EDGE-768x121.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27082907/CORZ-EDGE.png 1033w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were higher in premarket on Thursday. The SPY was up 0.39% at $614.24, while the QQQ advanced 0.46% to $548.73, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/06/46112471/ross-gerber-touts-an-idea-to-cut-deficit-by-trillions-of-dollars-let-the-tax-cuts-e">Ross Gerber Touts An Idea To Cut Deficit By Trillions Of Dollars: &#8216;Let The Tax Cuts Expire And Full SALT Come Back&#8217; </a></li>
</ul>
Image Credit: Shutterstock

$BTC

Core Scientific, Inc. - Class A Common Stock

CORZ

CRWV

MSFT

CRWV–CORZ Potential Deal Could Unlock $2.8 Billion Hidden Value For Bitcoin Miner, Says Morgan Stanley

TAL Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAL#NYSE">TAL</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $12.36, a high estimate of $16.00, and a low estimate of $10.90. Observing a downward trend, the current average is 18.79% lower than the prior average price target of $15.22. 
<img src="https://www.benzinga.com/files/images/story/2025/1751029278_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive TAL Education is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alice Cai</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.54</td>
<td>$13.40</td>
</tr>
<tr>
<td>Linda Huang</td>
<td>Macquarie</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$10.90</td>
<td>$14.50</td>
</tr>
<tr>
<td>DS Kim</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>DS Kim</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to TAL Education. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of TAL Education compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of TAL Education's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into TAL Education's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TAL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on TAL Education analyst ratings.</a>
<h2>Discovering TAL Education: A Closer Look</h2>
TAL Education Group is a smart learning solutions provider in China. It operates a few business lines including enrichment learning, high school academic tutoring, learning technology, and content solutions. Among those business lines, TAL focuses on enrichment learning and content solutions.
<h3>Unraveling the Financial Story of TAL Education</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: TAL Education's remarkable performance in 3M is evident. As of 28 February, 2025, the company achieved an impressive revenue growth rate of 42.06%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: TAL Education's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -1.2%, the company may face hurdles in effective cost management.
Return on Equity (ROE): TAL Education's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -0.19%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): TAL Education's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.13%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.09, TAL Education adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

4 Analysts Assess TAL Education: What You Need To Know

Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $10.2, a high estimate of $17.00, and a low estimate of $6.00. Highlighting a 5.38% decrease, the current average has fallen from the previous average price target of $10.78. 
<img src="https://www.benzinga.com/files/images/story/2025/1751029265_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Sprinklr among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Elizabeth Porter</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$10.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Clark Wright</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Michael Berg</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$7.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Matthew Vanvliet</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Neutral</td>
<td>$8.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Berg</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Elizabeth Porter</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$8.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Clark Wright</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sprinklr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sprinklr compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Sprinklr's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CXM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sprinklr analyst ratings.</a>
<h2>Discovering Sprinklr: A Closer Look</h2>
Sprinklr Inc is engaged in enabling customer-facing teams, from Customer Service to Marketing, to collaborate across internal silos, communicate across digital channels, and leverage AI to deliver customer experiences at scale all on one unified AI-based platform. It focuses on empowering companies to deliver next-generation, unified engagement journeys that reimagine the customer's experience. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights and Sprinklr Marketing. The company operates in the Americas, EMEA, and other countries. It derives maximum revenue from the Americas.
<h3>Breaking Down Sprinklr's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Sprinklr showcased positive performance, achieving a revenue growth rate of 4.87% as of 30 April, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Sprinklr's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.76% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Sprinklr's ROE stands out, surpassing industry averages. With an impressive ROE of -0.25%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Sprinklr's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.13% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.08.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Sprinklr Stock: A Deep Dive Into Analyst Perspectives (10 Ratings)

Biotech

General

CMND

Clearmind Medicine Adds Hadassah-University Medical Center As New Clinical Site For Phase I/IIa Trial Evaluating CMND-100

In the latest quarter, 8 analysts provided ratings for BeOne Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $324.38, with a high estimate of $350.00 and a low estimate of $311.00. This current average has decreased by 0.23% from the previous average price target of $325.14. 
<img src="https://www.benzinga.com/files/images/story/2025/1751029256_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of BeOne Medicines by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$311.00</td>
<td>$311.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$311.00</td>
<td>$312.00</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$350.00</td>
<td>$348.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$312.00</td>
<td>$312.00</td>
</tr>
<tr>
<td>Yaron Werber</td>
<td>TD Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$334.00</td>
<td>$334.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$317.00</td>
<td>$311.00</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$348.00</td>
<td>$348.00</td>
</tr>
<tr>
<td>Greg Renza</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$312.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to BeOne Medicines. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of BeOne Medicines compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of BeOne Medicines's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ONC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on BeOne Medicines analyst ratings.</a>
<h2>Get to Know BeOne Medicines Better</h2>
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
<h3>BeOne Medicines's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: BeOne Medicines's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 48.64%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 0.11%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): BeOne Medicines's ROE excels beyond industry benchmarks, reaching 0.04%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): BeOne Medicines's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.02% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: BeOne Medicines's debt-to-equity ratio is below the industry average. With a ratio of 0.28, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 8 Analyst Ratings Have To Say About BeOne Medicines

Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) has been analyzed by 26 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">13</td>
<td align="right">12</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">10</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Uber Technologies and provided 12-month price targets. The average target is $95.65, accompanied by a high estimate of $110.00 and a low estimate of $80.00. This current average has increased by 7.04% from the previous average price target of $89.36. 
<img src="https://www.benzinga.com/files/images/story/2025/1751029240_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Uber Technologies among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$84.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$106.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Mark Kelley</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Rob Sanderson</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$102.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$94.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Lloyd Walmsley</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$107.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$97.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Josh Beck</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Ross Sandler</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$97.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$98.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>John Blackledge</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$88.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$87.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Uber Technologies. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Uber Technologies compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Uber Technologies's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Uber Technologies's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/UBER/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Uber Technologies analyst ratings.</a>
<h2>About Uber Technologies</h2>
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food couriers, and shippers with carriers. The firm's on-demand technology platform is currently utilized by traditional cars as well as autonomous vehicles, but could eventually be used for additional products and services, such as delivery via drones or electronic vehicle take-off and landing (eVTOL) technology. Uber operates in over 70 countries, with over 170 million users who order rides or food at least once a month.
<h3>Key Indicators: Uber Technologies's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining Uber Technologies's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 13.84% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: Uber Technologies's net margin is impressive, surpassing industry averages. With a net margin of 15.4%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Uber Technologies's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 8.16%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Uber Technologies's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.41% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.51, Uber Technologies adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UBER

Forecasting The Future: 26 Analyst Projections For Uber Technologies

Mastercard's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) short percent of float has fallen 19.12% since its last report. The company recently reported that it has 4.99 million shares sold short, which is 0.55% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.18 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Mastercard Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751029232_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Mastercard has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Mastercard's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Mastercard's peer group average for short interest as a percentage of float is 6.57%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What's Driving the Market Sentiment Around Mastercard?

11 analysts have expressed a variety of opinions on Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Avidity Biosciences, presenting an average target of $67.0, a high estimate of $96.00, and a low estimate of $54.00. This current average has increased by 0.84% from the previous average price target of $66.44. 
<img src="https://www.benzinga.com/files/images/story/2025/1751029229_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Avidity Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Schmidt</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$96.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Andy Chen</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Freeman</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Strong Buy</td>
<td>$65.00</td>
<td>-</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$59.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$54.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$68.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Avidity Biosciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Avidity Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Avidity Biosciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/RNA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Avidity Biosciences analyst ratings.</a>
<h2>About Avidity Biosciences</h2>
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
<h3>Avidity Biosciences's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Negative Revenue Trend: Examining Avidity Biosciences's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -55.6% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Avidity Biosciences's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -7360.01%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Avidity Biosciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -8.41% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Avidity Biosciences's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -7.66%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.0, Avidity Biosciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Avidity Biosciences Through The Eyes Of 11 Analysts

ASTI

Ascent Solar Enters Into Teaming Agreement To Supply US-Based Defense Solutions Provider With Thin-Film Solar Technology Solutions For Upcoming Orbital Applications And Future Missions

IREN's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NYSE">IREN</a>) short percent of float has risen 19.88% since its last report. The company recently reported that it has 28.68 million shares sold short, which is 12.36% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.71 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>IREN Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751029226_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for IREN has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing IREN's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, IREN's peer group average for short interest as a percentage of float is 13.64%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

IREN

Is IREN Gaining or Losing Market Support?

Simon Property Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>) short percent of float has fallen 29.91% since its last report. The company recently reported that it has 3.54 million shares sold short, which is 1.64% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.57 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Simon Property Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751029221_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Simon Property Group has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Simon Property Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Simon Property Group's peer group average for short interest as a percentage of float is 6.08%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Simon Property Group's Recent Short Interest

Health Care

Legal

Press Releases

Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders

Financing

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

Earnings

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04

Adial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA Meeting

IPOs

Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply

Comments

Adial Pharmaceuticals

뉴스

에 대한 최신 뉴스 Adial Pharmaceuticals (NASDAQ:ADIL) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌